Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
26 results
D1.402 - Study of lymphocyte populations and subpopulations in patients with long-COVID with reactivation of herpesvirus type 6 infection
D1.397 - Eosinophilic Pneumonia Triggered by Toxocara canis in a Patient with Kartagener Syndrome: A Case Report Highlighting Diagnostic Challenges and Interdisciplinary Management
D1.398 - Retrospective study of the effect of bacterial immunotheraphy on patients with chronic respiratory diseases
D1.403 - Use of ketotifen as treatment for post viral infection cough in children
D1.404 - Use of inactivated polybacterial mucosal vaccine (IPMV) as part of the treatment for the reduction of recurrent acute respiratory infections
D1.405 - Immunological imprinting of IgG response to RV VP1 in children of the MAS and PAPS birth cohorts
D1.406 - The microbiota of the urogenital canal related to papillomavirus infection
D2.332 - Patients With HAE Report Positive Perceptions Following Berotralstat Treatment: Results from a Focus Group
D2.325 - Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
D2.326 - Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study
D2.327 - Outcome of hematopoietic stem cells transplantation for inborn error of immunity in Vietnam
D2.328 - Comparison of the frequency of viral infections in immunocompromised patients receiving immunoglobulin by different routes
D2.329 - Impact of Berotralstat on Quality of Life among Patients with Hereditary Angioedema: Pooled Analysis of the APeX-2 and APeX-J Trials
D2.330 - Hereditary angioedema prophylaxis therapy: berotralstat and lanadelumab safety profile
D2.331 - Lanadelumab safety and efficacy in patients aged ≥12 with hereditary angioedema (HAE) in China for long-term prophylaxis (LTP): An open-label, multicenter study
D2.334 - Real-World Effectiveness of Lanadelumab in Hereditary Angioedema: A 12-Month Retrospective Study at a Single Center in Colombia
D2.336 - Evolution of Hereditary Angioedema Prophylaxis in Hungary Over Four Decades (1979-2023)
D2.338 - The Effect of Covid-19 Vaccines on Adult Primary Immunodeficiency Patients
D2.339 - Hereditary Angioedema Burden: Impact on Quality of Life, Disease Management, and Sleep Health
D2.340 - A high prevalence of autoimmune diseases and autoantibodies in patients with hereditary angioedema in Sweden
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download